(7 of 7)
That same hope is echoed by dozens of other companies that have jumped into the race to perfect genome-based drugs--and nobody seems to doubt that it will eventually happen. While the genomics revolution hasn't touched most of our lives yet, the day when it will may not be far off. "When it starts to happen, it will happen quickly," predicts Adrian Hobden, president of Myriad Pharmaceuticals. "There will be a few brave pioneers who believe in it, and the vast majority will carry on as they've done before. Then over five years it will become an accepted standard of care, and everyone will be doing it."
--Reported by Dan Cray/San Francisco, Alice Park/Cambridge, Cathy Booth Thomas/Dallas, and Dick Thompson/Washington
TIME.com ON AOL Log on to AOL Wednesday at 7 p.m. E.T. to chat with Michael Lemonick. Keyword: TIME